4 September 2025

The latest Pharmacology and Therapeutics Advisory Committee (PTAC) meeting record is now available. It includes notes on ALYFTREK: A once daily CFTR modulator therapy currently undergoing initial evaluation with Pharmac.

Two things to note:

• It was marked as High Priority: for people with CF aged 6 years and older with a non-F508del mutation responsive only to ALYFTREK.
• Cost Neutral to currently funded Trikafta: for people with CF aged 6 years and older with a F508del or other mutation responsive to Trikafta.

If you'd like to read the full record, you can access it here>>